FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study

被引：0
|
作者：
Kumiko Umemoto
Hideaki Takahashi
Chigusa Morizane
Ikuhiro Yamada
Satoshi Shimizu
Kazuhiko Shioji
Yukio Yoshida
Masayo Motoya
Nobumasa Mizuno
Yasushi Kojima
Takeshi Terashima
Kazuhiro Uesugi
Makoto Ueno
Junji Furuse
Tetsuo Akimoto
Masafumi Ikeda
机构：
[1] National Cancer Center Hospital East,Department of Hepatobiliary and Pancreatic Oncology
[2] Juntendo University Graduate School of Medicine,Course of Advanced Clinical Research of Cancer
[3] Cancer Institute Hospital,Department of Gastroenterology
[4] Japanese Foundation For Cancer Research,Department of Gastroenterology
[5] Saitama Cancer Center,Department of Internal Medicine
[6] Niigata Cancer Center Hospital,Division of Gastrointestinal Oncology
[7] Shizuoka Cancer Center,Department of Gastroenterology and Hepatology
[8] Sapporo Medical University,Department of Gastroenterology
[9] Aichi Cancer Center Hospital,Department of Gastroenterology
[10] National Center for Global Health and Medicine,Department of Gastroenterology
[11] Kanazawa University Hospital,Departments of Gastroenterology
[12] National Hospital Organization Shikoku Cancer Center,Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division
[13] Kanagawa Cancer Center,Faculty of Medicine, Department of Medical Oncology
[14] Kyorin University,Department of Radiation and Oncology and Particle Therapy
[15] National Cancer Center Hospital East,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
UGT1A1 *28 or *6 polymorphism; Advanced pancreatic cancer; Irinotecan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：397 / 404
页数：7
相关论文
共 50 条
  • [1] FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1*28 and*6 polymorphism: a multicenter, retrospective study
    Umemoto, Kumiko
    Takahashi, Hideaki
    Morizane, Chigusa
    Yamada, Ikuhiro
    Shimizu, Satoshi
    Shioji, Kazuhiko
    Yoshida, Yukio
    Motoya, Masayo
    Mizuno, Nobumasa
    Kojima, Yasushi
    Terashima, Takeshi
    Uesugi, Kazuhiro
    Ueno, Makoto
    Furuse, Junji
    Akimoto, Tetsuo
    Ikeda, Masafumi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (03) : 397 - 404
  • [2] FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 polymorphism: A multicenter, retrospective study.
    Umemoto, Kumiko
    Takahashi, Hideaki
    Morizane, Chigusa
    Yamada, Ikuhiro
    Shimizu, Satoshi
    Shioji, Kazuhiko
    Yoshida, Yukio
    Motoya, Masayo
    Mizuno, Nobumasa
    Kojima, Yasushi
    Terashima, Takeshi
    Uesugi, Kazuhiro
    Ikeda, Masafumi
    Ueno, Makoto
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] Modified FOLFIRINOX in pancreatic cancer patients with double variant type of UGT1A1 polymorphism
    Umemoto, Kumiko
    Takahashi, Hideaki
    Watanabe, Kazuo
    Ohno, Izumi
    Shimizu, Satoshi
    Mitsunaga, Shuichi
    Shiba, Satoshi
    Ueno, Hideki
    Okusaka, Takuji
    Ikeda, Masafumi
    ANNALS OF ONCOLOGY, 2015, 26 : 95 - 95
  • [4] The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer
    Satake, Tomoyuki
    Morizane, Chigusa
    Maruki, Yuta
    Ohba, Akihiro
    Nagashio, Yoshikuni
    Kondo, Shunsuke
    Hijioka, Susumu
    Ueno, Hideki
    Okusaka, Takuji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (08) : 1331 - 1339
  • [5] The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer
    Tomoyuki Satake
    Chigusa Morizane
    Yuta Maruki
    Akihiro Ohba
    Yoshikuni Nagashio
    Shunsuke Kondo
    Susumu Hijioka
    Hideki Ueno
    Takuji Okusaka
    International Journal of Clinical Oncology, 2022, 27 : 1331 - 1339
  • [6] Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX
    Shirasu, Hiromichi
    Todaka, Akiko
    Omae, Katsuhiro
    Fujii, Hirofumi
    Mizuno, Nobumasa
    Ozaka, Masato
    Ueno, Hideki
    Kobayashi, Satoshi
    Uesugi, Kazuhiro
    Kobayashi, Noritoshi
    Hayashi, Hideyuki
    Sudo, Kentaro
    Okano, Naohiro
    Horita, Yosuke
    Kamei, Keiko
    Yukisawa, Seigo
    Kobayashi, Marina
    Fukutomi, Akira
    CANCER SCIENCE, 2019, 110 (02): : 707 - 716
  • [7] UGT1A1*28 POLYMORPHISM AND VOMITING IN ADVANCED COLORECTAL CANCER
    El Bastawisy, A. E.
    Farid, S. F.
    Bahnasy, A. A.
    El Zeiny, A. M.
    ANNALS OF ONCOLOGY, 2013, 24
  • [8] UGT1A1*28 polymorphism in ovarian cancer patients
    Cecchin, E
    Russo, A
    Corona, G
    Campagnutta, E
    Martella, L
    Boiocchi, M
    Toffoli, G
    ONCOLOGY REPORTS, 2004, 12 (02) : 457 - 462
  • [9] Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
    Vivaldi, C.
    Arrigoni, E.
    Morganti, R.
    Pecora, I.
    Fidilio, L.
    Catanese, S.
    Restante, G.
    Fornaro, L.
    Crucitta, S.
    Lencioni, M.
    Rofi, E.
    Vasile, E.
    Falcone, A.
    Danesi, R.
    Del Re, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
    Vivaldi, C.
    Arrigoni, E.
    Morganti, R.
    Catanese, S.
    Fidilio, L.
    Pecora, I.
    Restante, G.
    Fornaro, L.
    Crucitta, S.
    Lencioni, M.
    Rofi, E.
    Vasile, E.
    Falcone, A.
    Danesi, R.
    Del Re, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345